Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $255,919 | $161,194 | $117,880 | $122,119 |
| - Cash | $32,298 | $44,812 | $60,213 | $84,349 |
| + Debt | $201,056 | $207,098 | $216,142 | $221,290 |
| Enterprise Value | $424,677 | $323,480 | $273,809 | $259,060 |
| Revenue | $15,125 | $18,314 | $14,926 | $16,959 |
| % Growth | -17.4% | 22.7% | -12% | – |
| Gross Profit | $15,125 | $18,314 | $14,926 | $16,959 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$16,281 | -$15,398 | -$21,032 | -$19,855 |
| % Margin | -107.6% | -84.1% | -140.9% | -117.1% |
| Net Income | -$18,700 | -$18,255 | -$22,644 | -$22,290 |
| % Margin | -123.6% | -99.7% | -151.7% | -131.4% |
| EPS Diluted | -0.87 | -0.85 | -1.06 | -1.05 |
| % Growth | -2.4% | 19.8% | -1% | – |
| Operating Cash Flow | – | $17,506 | -$13,488 | -$16,801 |
| Capital Expenditures | – | -$155 | -$2,538 | -$8,745 |
| Free Cash Flow | – | $17,351 | -$16,026 | -$25,546 |